glp-1 news today cardiovascular outcomes 2025 november Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices Impact of GLP-1 receptor agonists
Description
Semaglutide slows down digestion, which means oral medications can potentially stay in the stomach longer, breaking down more before reaching the gut
GLP-1 drugs address only one type of inflammation
Most side effects during the first week are mild to moderate in severity and do not require discontinuation of therapy
Type 2 DM has a significant association with obesity and is characterized by insulin resistance
This may strengthen the case for studying GLP-1 medications as potentially helpful tools for both prevention and reducing the consequences of substance use in addiction care, especially for people who already have a clear medical reason to receive them
GLP-1 medications alone have robust safety data across thousands of patients
